360 results
8-K
EX-99.1
GOVX
Geovax Labs Inc
10 Aug 23
GeoVax Reports 2023 Second Quarter Financial Results
9:45am
of $4,669,214 ($0.47 per share) in 2022.
R&D Expenses: Research and development expenses were $4,719,728 and $7,538,917 for the three-month and six … :
Research and development
General and administrative
Loss from operations
Interest income
Net loss
Loss per common share
Condensed Consolidated Balance
424B5
GOVX
Geovax Labs Inc
18 Jul 23
Prospectus supplement for primary offering
4:13pm
COVID-19 vaccine and a gene-directed therapy against advanced head and neck cancer. Additional preclinical research and development programs include … research and development efforts, including extensive preclinical and clinical testing. All product candidates that we advance to clinical testing
8-K
EX-99.1
GOVX
Geovax Labs Inc
5 May 23
GeoVax Reports 2023 First Quarter Financial Results
8:48am
, or $0.34 per share, for the three months ended March 31, 2022.
R&D Expenses: Research and development expenses were $2,819,189 for the three months …
March 31,
Grant revenues
Operating expenses:
Research and development
General and administrative
Loss from operations
Other income (expense), net
Net
424B3
ou6rxhb
4 May 23
Prospectus supplement
4:09pm
424B3
vthivzsmmgd
4 May 23
Prospectus supplement
4:08pm
424B3
l5xp3ck9vq2csmjqk0
4 May 23
Prospectus supplement
4:08pm
8-K
EX-99.1
6oxu1 5abqulspk67
24 Mar 23
GeoVax Reports 2022 Year-End Financial Results
9:00am
POS AM
yghy540ppg0 sumty2
23 Mar 23
Prospectus update (post-effective amendment)
5:16pm
POS AM
uokbe zkzab
23 Mar 23
Prospectus update (post-effective amendment)
5:15pm
POS AM
em609 4869
23 Mar 23
Prospectus update (post-effective amendment)
5:15pm
8-K
EX-99.1
no22ql3py3euy fb7lea
14 Nov 22
GeoVax Reports 2022 Third Quarter
6:09am
8-K
EX-99.2
s33toyy
14 Nov 22
GeoVax Reports 2022 Third Quarter
6:09am
424B3
vddkq1
9 Nov 22
Prospectus supplement
4:03pm
424B3
eabkz91 ir0q8b
9 Nov 22
Prospectus supplement
4:02pm